CAS CDx
Complement Activation Signature. Companion diagnostic for a targeted, bifunctional complement inhibitor. Make rare diseases economically viable to pursue in clinical trials.
Projected Trial Savings
...
vs. standard ...-patient trial at $50K/patient
Enrichment
...
Biomarker-enriched enrollment
Signal Validated
...
Permutation test (1,000 shuffles)
How It Works
For this cohort and demo, we measure 5 complement system proteins spanning central, terminal, and alternative pathways (C3a, C5, C6, C5a, Factor B). An XGBoost classifier converts these into a probability score for complement-mediated pathology. Patients above the threshold are enrolled into your trial — concentrating the treatment-responsive population and reducing the sample size needed to detect efficacy.